Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Mar;79(929):159–163. doi: 10.1136/pmj.79.929.159

Urinalysis for interleukin-8 in the non-invasive diagnosis of acute and chronic inflammatory diseases

A Taha 1, V Grant 1, R Kelly 1
PMCID: PMC1742648  PMID: 12697917

Abstract

Background and aims: Given its role in mediating inflammation, the use of urinary interleukin-8 (IL-8) was assessed in the non-invasive diagnosis of acute and chronic inflammatory diseases.

Methods: IL-8 was measured by an enzyme linked immunosorbent assay in random urine samples (1 ml each) carrying code numbers and taken from 208 patients: 177 adults and 31 children presenting with a range of active or inactive inflammatory conditions.

Results: In the appropriate controls and in patients with inactive inflammation, the median urinary IL-8 levels ranged from 7–12 pg/ml, compared with 104 pg/ml in active ulcerative colitis (p = 0.002), 54 in active Crohn's disease (p = 0.025), 93 in active rheumatoid arthritis (p = 0.001), 107 in acute cholecystitis (p<0.0001), 127 in acute appendicitis (p = 0.0001), and 548 pg/ml in urinary tract infection (p<0.0001). Children with non-viral inflammation/infection also had higher IL-8 values (median, 199 pg/ml; p = 0.0001) than those with viral infection (median, 7 pg/ml) or non-specific conditions (median, 10 pg/ml). In the study group as a whole urinary IL-8 values correlated positively with peripheral blood white cell count (r = 0.32; p < 0.001), erythrocyte sedimentation rate (r = 0.41; p<0.001), and C-reactive protein (r = 0.33; p<0.001).

Conclusion: Taking the appropriate clinical situation into account, urinary IL-8 measurement helps in the non-invasive assessment of active inflammation in at least a number of common acute and chronic conditions.

Full Text

The Full Text of this article is available as a PDF (99.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Best W. R., Becktel J. M., Singleton J. W., Kern F., Jr Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976 Mar;70(3):439–444. [PubMed] [Google Scholar]
  3. Daig R., Andus T., Aschenbrenner E., Falk W., Schölmerich J., Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut. 1996 Feb;38(2):216–222. doi: 10.1136/gut.38.2.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. De Gendt C. M., De Clerck L. S., Bridts C. H., Van Osselaer N., Stevens W. J. Relationship between interleukin-8 and neutrophil adhesion molecules in rheumatoid arthritis. Rheumatol Int. 1996;16(4):169–173. doi: 10.1007/BF01419730. [DOI] [PubMed] [Google Scholar]
  5. Fagerhol M. K. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet. 2000 Nov 25;356(9244):1783–1784. doi: 10.1016/S0140-6736(00)03224-4. [DOI] [PubMed] [Google Scholar]
  6. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998 Jul;115(1):182–205. doi: 10.1016/s0016-5085(98)70381-6. [DOI] [PubMed] [Google Scholar]
  7. Grimm M. C., Elsbury S. K., Pavli P., Doe W. F. Interleukin 8: cells of origin in inflammatory bowel disease. Gut. 1996 Jan;38(1):90–98. doi: 10.1136/gut.38.1.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mack D. R. Ongoing advances in inflammatory bowel diseases, including maintenance therapies, biologic agents, and biology of disease. Curr Opin Pediatr. 1998 Oct;10(5):499–506. doi: 10.1097/00008480-199810000-00009. [DOI] [PubMed] [Google Scholar]
  9. Pepys M. B., Berger A. The renaissance of C reactive protein. BMJ. 2001 Jan 6;322(7277):4–5. doi: 10.1136/bmj.322.7277.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rothe L., Collin-Osdoby P., Chen Y., Sunyer T., Chaudhary L., Tsay A., Goldring S., Avioli L., Osdoby P. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology. 1998 Oct;139(10):4353–4363. doi: 10.1210/endo.139.10.6247. [DOI] [PubMed] [Google Scholar]
  11. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629. doi: 10.1056/NEJM198712243172603. [DOI] [PubMed] [Google Scholar]
  12. Stiemer B., Buschmann A., Bisson S., Hensel K., Gramm H. J., Hopp H., Weitzel H. K. Interleukin-8 in urine: a new diagnostic parameter for intra-amniotic infection after premature rupture of the membranes. Br J Obstet Gynaecol. 1997 Apr;104(4):499–502. doi: 10.1111/j.1471-0528.1997.tb11504.x. [DOI] [PubMed] [Google Scholar]
  13. Taha A. S., Kelly R. W., Carr G., Stiemer B., Morton R., Park R. H., Beattie A. D. Altered urinary interleukin-8/creatinine ratio in peptic ulcer disease: pathological and diagnostic implications. Am J Gastroenterol. 1996 Dec;91(12):2528–2531. [PubMed] [Google Scholar]
  14. Taub D. D., Oppenheim J. J. Chemokines, inflammation and the immune system. Ther Immunol. 1994 Aug;1(4):229–246. [PubMed] [Google Scholar]
  15. Tikhonov I., Rebenok A., Chyzh A. A study of interleukin-8 and defensins in urine and plasma of patients with pyelonephritis and glomerulonephritis. Nephrol Dial Transplant. 1997 Dec;12(12):2557–2561. doi: 10.1093/ndt/12.12.2557. [DOI] [PubMed] [Google Scholar]
  16. Troughton P. R., Platt R., Bird H., el-Manzalawi E., Bassiouni M., Wright V. Synovial fluid interleukin-8 and neutrophil function in rheumatoid arthritis and seronegative polyarthritis. Br J Rheumatol. 1996 Dec;35(12):1244–1251. doi: 10.1093/rheumatology/35.12.1244. [DOI] [PubMed] [Google Scholar]
  17. Van Zee K. J., DeForge L. E., Fischer E., Marano M. A., Kenney J. S., Remick D. G., Lowry S. F., Moldawer L. L. IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol. 1991 May 15;146(10):3478–3482. [PubMed] [Google Scholar]
  18. Yu Y., Chadee K. Entamoeba histolytica stimulates interleukin 8 from human colonic epithelial cells without parasite-enterocyte contact. Gastroenterology. 1997 May;112(5):1536–1547. doi: 10.1016/s0016-5085(97)70035-0. [DOI] [PubMed] [Google Scholar]
  19. de Boer E. C., Somogyi L., de Ruiter G. J., de Reijke T. M., Kurth K. H., Schamhart D. H. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res. 1997;25(1):31–34. doi: 10.1007/BF00941903. [DOI] [PubMed] [Google Scholar]
  20. van Setten P. A., van Hinsbergh V. W., van den Heuvel L. P., Preyers F., Dijkman H. B., Assmann K. J., van der Velden T. J., Monnens L. A. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome. Pediatr Res. 1998 Jun;43(6):759–767. doi: 10.1203/00006450-199806000-00008. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES